Mannitol dry powder for inhalation for treating cystic fibrosis

Cystic fibrosis - mannitol dry powder for inhalation: review consultation - May 2015 information

Cystic fibrosis - mannitol dry powder for inhalation: appendix A - matrix of stakeholders (PDF 98 KB)

Cystic fibrosis - mannitol dry powder for inhalation: appendix B - GE proposal paper May 2015 (PDF 454 KB)

TA266 Cystic fibrosis - mannitol dry powder for inhalation: press release information

Cystic fibrosis - mannitol: Equality Impact Assessment - Guidance development (PDF 19 KB)

Cystic fibrosis - mannitol: final appraisal determinaton information

Cystic fibrosis - mannitol: final appraisal determinaton (PDF 350 KB)

Cystic fibrosis - mannitol: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 183 KB)

Cystic fibrosis - mannitol: consultee and commentator comments on the ACD

Cystic fibrosis - mannitol: Pharmaxis (PDF 3 MB)

Cystic fibrosis - mannitol: Cystic Fibrosis Trust (PDF 59 KB)

Cystic fibrosis - mannitol: British Thoracic Society (the Royal College of Physicians supports these comments) (PDF 8.1 KB)

Cystic fibrosis - mannitol: Royal College of Nurses (PDF 19 KB)

Cystic fibrosis - mannitol: Department of Health (PDF 6.5 KB)

Cystic fibrosis - mannitol: Sandwell PCT (PDF 15 KB)

Cystic fibrosis - mannitol: Commissioning Support Appraisals Service (PDF 97 KB)

Cystic fibrosis - mannitol: Bilton (PDF 11 KB)

Cystic fibrosis - mannitol: comments on the ACD received from the public through the NICE website (PDF 342 KB)

Cystic fibrosis - mannitol: addendum to Evidence Review Group's Report following Pharmaxis' new evidence submission of 3rd July 2012 (PDF 327 KB)

Cystic fibrosis - mannitol: appraisal consultation

Cystic fibrosis - mannitol: appraisal consultation document information

Cystic fibrosis - mannitol: evaluation report

Cystic fibrosis - mannitol: pre-meeting briefing (PDF 209 KB)

Cystic fibrosis - mannitol: Evidence Review Group report (PDF 853 KB)

Cystic fibrosis - mannitol: Evidence Review Group report - factual accuracy check (PDF 38 KB)

Cystic fibrosis - mannitol: Pharmaxis (PDF 1.85 MB)

Cystic fibrosis - mannitol: clarification

Cystic fibrosis - mannitol: NICE clarification letter (PDF 38 KB)

Cystic fibrosis - mannitol: manufacturer response to the NICE clarification letter (PDF 435 KB)

Cystic fibrosis - mannitol: patient group, professional group and NHS organisation submission statements

Cystic fibrosis - mannitol: British Thoracic Society (PDF 24 KB)

Cystic fibrosis - mannitol: Royal College of Nursing (PDF 31 KB)

Cystic fibrosis - mannitol: Royal College of Paediatrics and Child Health (PDF 26 KB)

Cystic fibrosis - mannitol: Sandwell Primary Care Trust (PDF 53 KB)

Cystic fibrosis - mannitol: expert written personal statements

Cystic fibrosis - mannitol: Agent (PDF 29 KB)

Cystic fibrosis - mannitol: Bilton (PDF 34 KB)

Cystic fibrosis - mannitol: Lake (PDF 36 KB)

Cystic fibrosis - mannitol: Macherianakis (PDF 20 KB)

Mannitol - cystic fibrosis: final scope (PDF 40 KB)

Mannitol - cystic fibrosis: final matrix of consultees and commentators (PDF 30 KB)

Mannitol - cystic fibrosis: Institute's response to consultee and commentator comments on the draft scope (PDF 86 KB)

Mannitol - cystic fibrosis: Institute's response to consultee and commentator comments on the provisional matrix (PDF 25 KB)

Mannitol - cystic fibrosis: draft scope (PDF 44 KB)

Mannitol - cystic fibrosis: provisional matrix (PDF 55 KB)